Legend Biotech Announces Acceptance of Its New Drug Applicat

02.01.2023 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that China’s National Medical Products ...

Related Keywords

China , Japan , United States , New Jersey , Chinese , American , Hemophagocytic Lymphohistiocytosis , Saijuan Chen , Ying Huang , American Society Of Clinical Oncology , Janssen Biotech Inc , Exchange Commission On , Linkedin , Twitter , Chinese Center , European Commission For The Treatment Of Patients , Legend Biotech Corporation Stock , Japan Ministry Of Health , Legend Biotech Corporation , Drug Evaluation Of National Medical Products Administration , Community Register Of Orphan Medicinal Products , American Cancer Society , Drug Administration , European Commission , Medicinal Devices Agency , Academician Of The Chinese Academy Engineering , European Medicines Agency , Chinese Academy , Chief Executive Officer , Legend Biotech , Janssen Biotech , Breakthrough Therapy Designation , Drug Designation , Orphan Medicinal Products , Release Syndrome , Effector Cell Associated Neurotoxicity Syndrome , Macrophage Activation Syndrome , Risk Evaluation , Mitigation Strategy , Nerve Palsies , Recurrent Cytopenias , Igg Hypersensitivity Reactions , Use Machines , Prescribing Information , Boxed Warning , Private Securities Litigation Reform Act , Drug Evaluation , National Medical Products Administration , Annual Report , Exchange Commission , Adult Patients , Refractory Multiple , Accessed October , Granted Conditional Approval , Receives Approval , Community Register , Orphan Medicinal , Fact Sheet , Accessed December ,